加拿大原住民慢性肾脏病筛查具有成本效益
研究构建决策分析马尔可夫模型,比较筛查并治疗慢性肾脏病(CKD)与常规护理在加拿大农村原住民成人中的成本效用。筛查相较常规护理的增量成本效果比(ICER)为23700美元/质量调整生命年(QALY);仅限航空交通社区(CKD患病率34.4%)时降至7790美元/QALY,公路可达社区(17.6%)为52480美元/QALY。模型对关键变量单变量敏感性分析稳健,概率敏感性分析显示50000美元/QALY阈值下72%模拟具有成本效益、100000美元/QALY阈值下93%具有成本效益。
要点
- 加拿大原住民肾衰竭发生率是非原住民普通人群的2至4倍。
- 农村原住民CKD筛查与治疗的ICER为23700美元/QALY。
- 仅航空交通社区CKD患病率34.4%,ICER降至7790美元/QALY。
核心结论
- 使用即时检测设备对加拿大农村原住民进行CKD靶向筛查和治疗具有成本效益,在CKD和肾衰竭风险最高的偏远航空交通社区尤为明显。
- 作者建议通过整群随机对照试验评估靶向筛查举措,并建议将筛查整合到风险最高社区的常规临床就诊中。
研究设计与样本
- 构建决策分析马尔可夫模型,比较筛查并治疗策略与常规护理,对象为加拿大农村原住民成人,筛查依据估算肾小球滤过率和尿白蛋白与肌酐比值。
- 主要结局为增量成本效果比(ICER),以每质量调整生命年(QALY)的成本表示。
主要发现
- 筛查CKD相较常规护理的ICER为23700美元/QALY。
- 仅限航空交通社区(CKD患病率34.4%)时ICER降至7790美元/QALY。
- 公路可达社区(CKD患病率17.6%)的ICER为52480美元/QALY。
- 单变量敏感性分析中模型对 influential 变量的变化稳健;概率敏感性分析显示50000美元/QALY阈值下72%的模拟具有成本效益、100000美元/QALY阈值下93%的模拟具有成本效益。
临床怎么用
- 作者建议通过整群随机对照试验评估靶向筛查举措,并建议将筛查整合到风险最高社区的常规临床就诊中。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Canadian indigenous (First Nations) have rates of kidney failure that are 2- to 4-fold higher than the non-indigenous general Canadian population. As such, a strategy of targeted screening and treatment for CKD may be cost-effective in this population. Our objective was to assess the cost utility of screening and subsequent treatment for CKD in rural Canadian indigenous adults by both estimated glomerular filtration rate and the urine albumin-to-creatinine ratio. A decision analytic Markov model was constructed comparing the screening and treatment strategy to usual care. Primary outcomes were presented as incremental cost-effectiveness ratios (ICERs) presented as a cost per quality-adjusted life-year (QALY). Screening for CKD was associated with an ICER of $23,700/QALY in comparison to usual care. Restricting the model to screening in communities accessed only by air travel (CKD prevalence 34.4%), this ratio fell to $7,790/QALY. In road accessible communities (CKD prevalence 17.6%) the ICER was $52,480/QALY. The model was robust to changes in influential variables when tested in univariate sensitivity analyses. Probabilistic sensitivity analysis found 72% of simulations to be cost-effective at a $50,000/QALY threshold and 93% of simulations to be cost-effective at a $100,000/QALY threshold. Thus, targeted screening and treatment for CKD using point-of-care testing equipment in rural Canadian indigenous populations is cost-effective, particularly in remote air access-only communities with the highest risk of CKD and kidney failure. Evaluation of targeted screening initiatives with cluster randomized controlled trials and integration of screening into routine clinical visits in communities with the highest risk is recommended.
引用
- Ferguson TW, Tangri N, Tan Z, et al. Screening for chronic kidney disease in Canadian indigenous peoples is cost-effective. Kidney Int. 2017. PMID: 28433383. doi:10.1016/j.kint.2017.02.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。